**Name of journal: World Journal of Nephrology**

**ESPS Manuscript NO: 12014**

**Columns: MINIREVIEWS**

**Role of β2-microglobulin in uremic patients may be greater than originally suspected**

Zumrutdal A. β2-microglobulin in uremic patients

Aysegul Zumrutdal

**Aysegul Zumrutdal**, Nephrology Department, Baskent University Adana Teaching and Research Center, Baskent University Hospital, Yuregir, Adana 01230, Turkey

**Author contributions:** Zumrutdal A solely contributed to this work.

**Correspondence to**: **Aysegul Zumrutdal**, **MD, Professor**, Nephrology Department, Baskent University Adana Teaching and Research Center, Baskent University Hospital, Yuregir, Dadaloglu Mah, 2591 St, 4/A, Adana 01230, Turkey. azumrutdal@yahoo.com

**Telephone:** +90-322-3272727 **Fax:** +90-322-3271274

**Received:** June 17, 2014 **Revised:** September 3, 2014

**Accepted:** October 1, 2014

**Published online:**

**Abstract**

The role of beta2-microglobulin (β2M) in dialysis-related amyloidosis as a specific amyloid precursor was defined in the 1980s. Studies in those years were largely related to β2M amyloidosis. In 2005, for what was probably the first time in the available literature, we provided data about the association between β2Mand early-onset atherosclerosis in hemodialysis patients without co-morbidities. In recent years, the role of uremic toxins in uremic atherosclerosis and the interest in β2Mas a marker of cardiovascular (CV) and/or mortality risk have grown. In the current literature, clinical studies suggest that β2M is an independent, significant predictor of mortality not only in dialysis patients but also in predialysis patients and in the high-risk portion of the general population, and it seems to be a factor strongly linked to the presence and severity of CV disease. It is still unknown whether β2M is only a uremic toxin marker or if it also has an active role in vascular damage, but data support that it may reflect an increased burden of systemic atherosclerosis in a setting of underlying chronic kidney disease. Thus, although there have been some inconsistencies among the various analyses relating to β2M, it promises to be a novel risk marker of kidney function in the awareness and detection of high-risk patients. However, more research is required to establish the pathophysiologic relationships between retained uremic toxins and further biochemical modifications in the uremic milieu to get answers to the questionsof why and how.In this review, the recent literature about the changing role of β2M in uremic patients will be examined.

©2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** β2–microglobulin; Carotid atherosclerosis; Cardiovascular disease; Cardiovascular risk; Coronary artery disease; Hemodialysis; Mortality; Uremia; Uremic toxins

**Core tip:** Previously, the clinical significance of β2–microglobulin (β2M) in uremic patients was limited to β2M-derived amyloidosis; in recent years, its role and power has changed and expanded. Although there have been some inconsistencies among the various analyses relating to β2M, the data generally support β2M as a promising novel marker of kidney function by predicting cardiovascular (CV) risk, CV events and overall mortality.

Zumrutdal A. Role of β2-microglobulin in uremic patients may be greater than originally suspected. *World J Nephrol* 2014, In press

**INTRODUCTION**

β2–microglobulin (β2M) forms the non-variable light chain of the Class 1 major histocompatibility complex (MHC). It is found on the surfaces of nearly all nucleated cells. It is a nonglycosylated polypeptide with a molecular weight of 11.729Da[1,2]. Due to its small size, β2M is present in the glomerular filtrate of the normal kidney. It was originally discovered as a component present in the urine of patients with tubular proteinuria. In human lymphocytes, it has been estimated that there are 105-106β2M molecules/cell. When MHC is degraded, the MHC-associated β2M is released into circulation[2-4]. This results in a constant production of free β2M at a level of 0.13 mg/h × body weight in kilograms under normal conditions[2]. β2Mis found in low concentrations as a conformationally less restricted free monomer in blood and other biofluids, including synovial fluid. The normal physiological function, if any, of the freely circulating β2M is unknown[2]. The β2M synthesis rate in healthy individuals ranges from 2 mg/kg per day to 4 mg/kg per day, with a half-life of 2.5 h, and plasma concentrations vary between 1 mg/mL and 3 mg/mL[5].

Elevated β2M levels are observed in chronic renal failures, lymphoproliferative disorders, inflammations, infections, and other conditions as well, with high cell turnover[2]. A relationship has been noted between tumor burden and β2M[6]. Concerning its use in oncology, β2M levels correlate with the disease stage and poorer prognosis in patients with multiple myeloma and chronic lymphocytic leukemia[6,7]. And it is the most important predictor of treatment-free survival and overall survival of patients affected by lymphocytic leukemia and in most cases of lymphatic neoplasia. Additionally, serum β2M levels can help to predict outcome in patients > or = 60 years with untreated acute myeloid leukemia[6,8]. Therefore, it is emphasized that β2M may be the subject of future target therapy in cancer research[9].

Given that β2M elimination is achieved *via* glomerular filtration, it is not surprising that plasma levels are inversely related to the glomerular filtration rate. Levels can be elevated as much as 60-fold in anuric patients with end-stage renal disease[5]. β2M is a well-known, frequently studied representative marker of middle-molecule uremic toxins and its role in dialysis-related amyloidosis as a specific amyloid precursor was defined in the 1980s[10]. Previous studies have largely been related to β2M amyloidosis. However, its relationship with vascular risk was not identified until 2005. That year, to our knowledge for the first time in the available literature, we provided data on this relationship. We showed that, besides well-known cardiovascular (CV) risk factors, β2M levels were independently related with carotid artery intima media thickness (C-IMT) in non-diabetic hemodialysis (HD) patients who had no clinical evidence of atherosclerosis[11]. Since then, the number of studies concerning this relationship has increased, and now β2M’s direct pathophysiological role in vascular disease and its power as a predictor of overall and CV events are more predominant in the literature. In this review, the recent literature about the changing role of β2M in uremic patients will be examined.

**β2M -DERIVED AMYLOID**

In long term dialysis patients, retention of β2M produces a disease related to the deposition of β2M amyloid fibrils around large joints such as shoulders and hips. In 1980, Assenat *et al*[12] were the first to report finding amyloid in the material they had excised from their patients’ carpal tunnels. And in 1985, Gejyo *et al*[13] established a novel type of amyloidosis in patients undergoing HD. Initially, it was believed to occur only in patients on chronic HD; therefore, it was called “dialysis-associated amyloidosis”. However, it soon became clear that amyloidosis could develop in patients on any type of renal replacement therapy and even in uremic and predialysis patients. Therefore, it came to be referred to as β2M -derived amyloid or in line with general amyloid terminology, as A β2M -amyloid[5] .

***Pathogenesis***

The exact mechanism of amyloidogenesis in dialysis patients remains unclear, however elevation of circulating β2M levels may not be the only cause of β2M derived amyloid. Recent studies have emphasized that in addition to substrate retention, biochemical modification of the β2M molecule (such as oxidative modification) in the uremic milieu may potentiate its pathogenicity[14]. Glycosylated β2M, a modified microglobulin, has been found in amyloid deposits as advanced glycation end products. This may further enhance the development of the lesions by both stimulating the secretion of cytokines and acting as chemoattractant and an apoptosis-delaying agent for monocytes. However, it remains unknown whether this modification plays an active role or is merely a long-term transformation of long-lived amyloid fibrils[14-17].

One of the other pathogenetic concepts in β2M-derived amyloidosis is limited proteolysis and partial breakdown of native β2M[5]. In recent years, a cleavage product form of β2M that has a deletion of lysine at position 58 on the molecule ∆K58- β2M and behaves differently from normal β2M has been demonstrated in the sera of 20%-40% of dialysis patients[18]. Although it is conformationally unstable and amyloidogenic *in vitro*, it was suggested that it could play a role in β2M amyloid fibrillogenesis[19]. However, it was not detected by 2D electrophoresis in the *ex vivo* amyloid fibrils of two patients affected by dialysis-related amyloidosis[20]. Based on this result, the authors concluded that the process of amyloid deposition “in a target tissue requires that the fibrillogenic protein attains the amyloidogenic conformation at the right site, at the right time, and at the right concentration”. They further speculated that ∆K58- β2M might be more susceptible to degradation than to amyloid deposition. In contrast, an N-terminal truncated species lacking six residues, ∆N6- β2M, which was highly amyloidogenic *in vitro*, was not detectable in plasma[20]. The list of factors that have been shown to influence the conformation of intact β2M is very long. However, many of the *in vitro* conditions that are highly favorable for amyloid formation from normal β2M are not encountered *in vivo* because of the possibility that several factors may interplay in different ways *in vivo*[5].

***Clinical manifestations/diagnosis***

This is a systemic type of amyloidosis, but clinical manifestations of the disease are largely confined to the musculoskeletal system with: carpal tunnel syndrome, spondyloarthropathies, hemarthrosis, joint pain and immobility. Late in the course of the disease, systemic deposition can occur, principally in the gastrointestinal tract and heart. Ninety percent of the patients may have the disease pathologically, but not manifest clinical symptoms. Additionally, clinical symptoms are often nonspecific and easily mistaken for other articular disorders. The manifestations of β2M appear gradually over the course of years, between two and ten years after the start of dialysis in the majority of patients[2,5,21].

There are some suggestive findings, but no pathognomonic clinical or radiologic findings exist in β2M amyloidosis. The gold standard diagnostic technique to demonstrate positive Congo Red staining and the presence of β2M is biopsy. And diagnostic material usually has to be obtained from synovial membranes or bone lesions[5,21].

***Treatment***

There have been many studies addressing the effects of different dialysis membranes on serum β2M levels. Generally, it is recommended that non-cuprophane, high-flux dialyers should be used to patients with evidence of, or at risk for, β2M amyloidosis[21]. High-volume hemodiafiltration and ultrapure dialysate were also reported to be associated with increased β2M removal, lower serum concentrations and reduced inflammation[21-23]. However, dialysis of any kind or with any membrane is incapable of removing sufficient quantities of β2M to completely prevent the deposition of amyloid. And, with the exception of kidney transplantation, no currently available therapy can stop the disease progression of β2M amyloidosis or provide symptomatic relief[21].

**β2M AND CARDIOVASCULAR RISK**

In recent years, progressively more studies have been conducted with the aim of showing the involvement of uremic toxins and endothelial dysfunction in several aspects of uremic atherosclerosis[24]. Related with this, interest has grown in β2M as a marker of kidney function and CV risk.

***Pathogenesis***

The role of serum β2M in the pathogenesis of CV disease still is not clearly known. However, there have been some suggestions. For example, β2M appears to damage vessels by participating in amyloid formation in the vascular wall[25]. Also, retained uremic solutes, such as β2M advanced glycosylated end products which have been substrates for oxidative injury, seem to further contribute to the proatherogenic milieu of uremia[14]. Additionally, it has been demonstrated that some uremic toxins inhibit endothelial proliferation and wound repair in uremic patients[26]. In the presence of uremic serum, endothelial progenitor cells, which contribute to vessel repair and neovascularization, undergo a decrease in their ability to migrate[27]. The influence of the uremic milieu was confirmed by the observation that high serum levels of β2M and indole-3-acetic acid were associated with low numbers of circulating CD34+CD133+ endothelial progenitor cells[28]. Another study investigated whether β2M was proinflammatory by inducing oxidative burst in leukocytes; β2M was not found to be a factor for induction of leukocyte free radical production[29]. However, the involvement of β2M in the inflammatory process and its association with vascular risk is still an area of interest deserving attention.

***Carotid Atherosclerosis***

 In 2005, we investigated the associations of different risk factors with C-IMT, which had been an early marker of atherosclerosis, in “healthy”, non-diabetic HD patients who had no clinical evidence of atherosclerosis[11]. In multivariate regression analysis, age, β2M, C-reactive protein and left ventricular hypertrophy were independently related with C-IMT. Elevated levels of β2M were found to be correlated not with the inflammatory markers but with the time patients had been in a uremic state. As we explained, although elevated plasma β2M was a well-known characteristic of the chronic renal failure, that correlation may be just an epiphenomenon rather than a causal relationship, or β2M levels may indirectly influence uremia-related CV risk factors, or β2M *per se* may contribute to atherogenesis. As these were probably the first data about the importance of β2M as a CV risk factor in uremic patients, our findings necessitated confirmation in additional, larger scale studies. In 2006, using the same patient group, we assessed the determinants of the progression of C-IMT over the course of one year[30]. As in our former study, β2M was independently related with C-IMT at baseline; however, age and sex were the only independent predictors of the progression in C-IMT from baseline to the 12-month stage. Subsequent studies in the general population showed that β2M was independently and significantly associated with total mortality and adverse CV outcome in patients with prevalent asymptomatic carotid atherosclerosis.

***Peripheral arterial disease***

 In 2007, in the general population, Wilson *et al*[25]researched patients with and without peripheral arterial disease (PAD) and analyzed their plasma. The peak intensity of a 12 kDa protein was higher in patients with PAD. Western blot analyses and immunoaffinity studies confirmed that that protein was β2M and circulating β2M in PAD patients was elevated and correlated with the severity of the disease. Another study found no relationship between β2M and the augmentation index either in patients with PAD or in healthy subjects. However, it did demonstrate that among patients with PAD, elevated plasma β2M levels were associated with higher aortic stiffness irrespective of CV disease risk factors[31]. Subsequent studies did not support this association between β2M and PAD[32]. Additionally, no changes were found in β2M levels in PAD patients after exercise on a treadmill, thus challenging the initial hypothesis by Wilson *et al*[33] of an increase in β2M levels in patients with PAD due to repeated bouts of ischemia-reperfusion. Although the conflicting results mostly pointed to a non-specific elevation of β2M in patients with a high vascular risk, it was concluded that β2M levels may not indicate the presence of PAD, but may instead reflect an increased burden of systemic atherosclerosis in a setting of underlying chronic kidney disease (CKD)[31,32,34].

***Coronary artery disease***

In 2007, we evaluated the determinants of coronary artery disease (CAD) other than conventional risk factors in nondiabetic HD patients[35]. Patients with CAD were compared to those without, and although β2M levels were higher in CAD patients (5.4±1.4 *vs* 4.8±1.5 mg/dL), the difference between the groups was not found to be statistically significant. The association between CV risk markers and arterial calcification in patients with CKD at Stages 3 and 4 had only recently been studied and β2M found to be associated with coronary artery calcification beyond some other inflammatory biomarkers[36]. In addition, β2M, along with cystatin C and C-reactive protein, were found to predict mortality and improve risk classification and discrimination for a high-risk cohort undergoing coronary angiography[37].

***Acute heart failure***

In a study evaluating the prognostic role of serum β2M in heart failure, patients with severe renal dysfunction were excluded and a higher baseline serum β2M concentration was found to be the most powerful predictor of cardiac events and cardiac mortality in acute heart failure patients with creatinine ≤ 3.0 mg/dL. Furthermore, the baseline serum β2M concentration had a superior ability to distinguish cardiac-event risk in acute heart failure patients compared with creatinine-based renal parameters[38].

***Left atrial size***

A linear correlation was found between the circulating levels of β2M and cystatin C, and left atrial diameters. Additionally, left atrial diameters were negatively related to creatinine clearance in two study groups, one with CAD and the other without[39].

***Arterial stiffness***

Arterial stiffness occurs due to loss of compliance of the vascular wall. It is a prominent feature of vascular ageing, and strongly predicts CV and total mortality**.** β2M has been shown to be related to arterial stiffness in the general population[40]. In HD patients, β2M levels were found to be positively associated with pulse pressure, which is a result of arterial stiffness. Additionally, β2M levels were positively associated with insulin resistance[41].

**β2M AND ALL-CAUSE AND CARDIOVASCULAR MORTALITY**

The HEMO study on 1704 HD patients showed that the predialysis serum β2M predicted mortality. After making statistical adjustments for the number of years on dialysis and for residual kidney function, for every 10 mg/L increase in the β2M level, there was a corresponding increase of 11% in mortality. The specific causes of death that account for this increased mortality have not been determined[42]. Another study evaluated the association of β2M levelsin 490 HD patients with their clinical outcomes by dividing them into two groups according to their serum β2M levels[43]. Mortality from all causes in the higher β2M group was found to be significantly higher compared to that in the lower β2M group. These results demonstrated that serum β2M was a significant predictor of mortality in HD patients, independent of HD duration, diabetes, malnutrition and chronic inflammation[43].

The impact of β2M was studied in patients with CKD at different stages not yet on dialysis[44]. Baseline β2M levels were associated with vascular calcification but not with arterial stiffness. Higher β2M levels were independently associated with overall and CV mortality, with CV events in the whole cohort, and with CV events in the predialysis cohort. Furthermore, serum β2M was identified as an independent predictor of all-cause mortality in a population-based sample of older adults. Also, β2M was identified as a novel risk marker for adverse CV outcomes in patients with carotid atherosclerosis[45].

***β2M and infectious mortality in hemodialysis patients***

The HEMO Study Group examined the association of serum β2M levels and dialyzer β2M kinetics with cause-specific mortality. They focused on cardiac and infectious diseases, which were the most common causes of death. There was no statistically significant associationin that study between cumulative mean predialysis serum β2M levels and cardiac mortality. However, in the entire cohort, each 10-mg/L increase in serum β2M level was associated with a 21% increase in the rate of infectious mortality[46].

***β2M and mortality and graft loss***

The association between post-transplant serum β2M and the outcomes following kidney transplantation was investigated. Serum β2M at discharge was a potent predictor of long-term mortality and of graft loss in kidney transplant recipients, providing information on the allograft function beyond that of serum creatinine[47].

**ENCAPSULATING PERITONEAL SCLEROSIS**

This is a serious complication in peritoneal dialysis patients. β2M was found to be a useful screening test for the onset of encapsulating peritoneal sclerosis, and β2M and the accumulation of middle-molecular uremic toxins were thought to be related with the pathophysiology of this disease[48]. Recently, the accumulation of advanced glycation end products and β2M in the fibrotic thickening of the peritoneum in long-term peritoneal dialysis patients was investigated. The proportion of β2M-expressing areas was found to be elevated in long term peritoneal dialysis patients, which may be a marker of peritoneal injury[49].

**β2M AS A NOVEL MARKER OF KIDNEY FUNCTION AND RISK PREDICTION**

Recently, there have been studies which evaluated whether novel biomarkers could add any information to improve risk prediction in patients at moderate and high risk. Data have provided that β2M, cystatin C and C-reactive protein predict mortality and improve risk classification and discrimination for a high-risk cohort. β2M and, to a lesser extent, beta trace protein, shared cystatin C’s advantage over serum creatinine-based estimated GFR in predicting outcomes, including kidney failure. Thus, β2M shows promise as a novel filtration marker of kidney function for risk prediction of all-cause and CV mortality[50- 52].

**CONCLUSION**

Previously, the clinical significance of β2M in uremic patients was limited to β2M-derived amyloidosis; in recent years, its role and power have changed and expanded. Although there were some inconsistencies among the various analyses relating β2M to clinical outcomes, the data generally support β2M as a promising novel marker of kidney function by predicting CV risk, CV events and overall mortality. It still remains unclear the exact role β2M plays in CV events and why it predicts CV and high risk of morbidity and mortality. Further studies are needed to clarify the role of β2M in uremic patients.

**REFERENCES**

1 **Vincent C**, Revillard JP. Beta-2-microglobulin and HLA-related glycoproteins in human urine and serum. *Contrib Nephrol* 1981; **26**: 66-88 [PMID: 6169488]

2 **Corlin DB**, Heegaard NH. β(2)-microglobulin amyloidosis. *Subcell Biochem* 2012; **65**: 517-540 [PMID: 23225015 DOI: 10.1007/978-94-007-5416-4-19]

3 **Björck L**, Akerström B, Berggård I. Occurrence of beta 2-microglobulin in mammalian lymphocytes and erythrocytes. *Eur J Immunol* 1979; **9**: 486-490 [PMID: 91519 DOI: 10.1002/eji.1830090613]

4 **Cresswell P**, Springer T, Strominger JL, Turner MJ, Grey HM, Kubo RT. Immunological identity of the small subunit of HL-A antigens and beta2-microglobulin and its turnover on the cell membrane. *Proc Natl Acad Sci U S A* 1974; **71**: 2123-2127 [PMID: 4134761 DOI: 10.1073/pnas.71.5.2123]

5 **Floege J.** Beta2-microglobulin derived amyloid. Johnson R, Feehaly J, editors. Comprehensive Clinical Nephrology (Spain): Mosby-Elsevier, 2003: 921-929

6 **Coppolino G**, Bolignano D, Rivoli L, Mazza G, Presta P, Fuiano G. Tumour markers and kidney function: a systematic review. *Biomed Res Int* 2014; **2014**: 647541 [PMID: 24689048 DOI: 10.1155/2014/647541]

7 **Rossi D**, Fangazio M, De Paoli L, Puma A, Riccomagno P, Pinto V, Zigrossi P, Ramponi A, Monga G, Gaidano G. Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. *Cancer* 2010; **116**: 2188-2200 [PMID: 20198709 DOI: 10.1002/cncr.24959]

8 **Tsimberidou AM**, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. *Clin Cancer Res* 2008; **14**: 721-730 [PMID: 18245532 DOI: 10.1158/1078-0432.CCR-07-2063]

9 **Shi C**, Zhu Y, Su Y, Chung LW, Cheng T. Beta2-microglobulin: emerging as a promising cancer therapeutic target. *Drug Discov Today* 2009; **14**: 25-30 [PMID: 19056512 DOI: 10.1016/j.drudis.2008.11.001]

10 **Fujimori A**. Beta-2-microglobulin as a uremic toxin: the Japanese experience. *Contrib Nephrol* 2011; **168**: 129-133 [PMID: 20938132 DOI: 10.1159/000321751]

11 **Zumrutdal A**, Sezer S, Demircan S, Seydaoglu G, Ozdemir FN, Haberal M. Cardiac troponin I and beta 2 microglobulin as risk factors for early-onset atherosclerosis in patients on haemodialysis. *Nephrology (Carlton)* 2005; **10**: 453-458 [PMID: 16221094 DOI: 10.1111/j.1440-1797.2005.00475.x]

12 **Assenat H**, Calemard E, Charra B, Laurent G, Terrat JC, Vanel T. [Hemodialysis: carpal tunnel syndrome and amyloid substance]. *Nouv Presse Med* 1980; **9**: 1715 [PMID: 7465408]

13 **Gejyo F**, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, Suzuki M, Hirasawa Y, Shirahama T. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin. *Biochem Biophys Res Commun* 1985; **129**: 701-706 [PMID: 3893430 DOI: 10.1016/0006-291X(85)91948-5]

14 **Himmelfarb J**, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. *Kidney Int* 2002; **62**: 1524-1538 [PMID: 12371953 DOI: 10.1046/j.1523-1755.2002.00600.x]

15 **Kay J,** Henrich WL, Qunibi W. Dialysis related amyloidosis. Berns JS, Schwab SJ, editors. Massachusetts, USA; 2014

16 **Miyata T**, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda K, Seo H. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. *J Clin Invest* 1994; **93**: 521-528 [PMID: 8113390 DOI: 10.1172/JCI117002]

17 **Niwa T**, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Saito A, Miyazaki S, Maeda K, Tatemichi N, Takei Y. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. *Kidney Int* 1996; **49**: 861-867 [PMID: 8648931 DOI: 10.1038/ki.1996.119]

18 **Corlin DB**, Sen JW, Ladefoged S, Lund GB, Nissen MH, Heegaard NH. Quantification of cleaved beta2-microglobulin in serum from patients undergoing chronic hemodialysis. *Clin Chem* 2005; **51**: 1177-1184 [PMID: 15890888 DOI: 10.1373/clinchem.2005.049544]

19 **Winchester JF**. Novel changes in beta2-microglobulin in dialysis patients. *Clin Chem* 2005; **51**: 1089-1090 [PMID: 15976094 DOI: 10.1373/clinchem.2005.051698]

20 **Giorgetti S**, Stoppini M, Tennent GA, Relini A, Marchese L, Raimondi S, Monti M, Marini S, Østergaard O, Heegaard NH, Pucci P, Esposito G, Merlini G, Bellotti V. Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. *Protein Sci* 2007; **16**: 343-349 [PMID: 17242436 DOI: 10.1110/ps.062563507]

21 **National Kidney Foundation.** K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis* 2003; **42**: S1-S201 [PMID: 14520607]

22 **Lonnemann G**, Koch KM. Beta(2)-microglobulin amyloidosis: effects of ultrapure dialysate and type of dialyzer membrane. *J Am Soc Nephrol* 2002; **13** Suppl 1: S72-S77 [PMID: 11792765]

23 **Fry AC**, Singh DK, Chandna SM, Farrington K. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. *Blood Purif* 2007; **25**: 295-302 [PMID: 17622712 DOI: 10.1159/000104870]

24 **Vanholder R**, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J. A bench to bedside view of uremic toxins. *J Am Soc Nephrol* 2008; **19**: 863-870 [PMID: 18287557 DOI: 10.1681/ASN.2007121377]

25 **Wilson AM**, Kimura E, Harada RK, Nair N, Narasimhan B, Meng XY, Zhang F, Beck KR, Olin JW, Fung ET, Cooke JP. Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. *Circulation* 2007; **116**: 1396-1403 [PMID: 17724262 DOI: 10.1161/CIRCULATIONAHA.106.683722]

26 **Brunet P**, Gondouin B, Duval-Sabatier A, Dou L, Cerini C, Dignat-George F, Jourde-Chiche N, Argiles A, Burtey S. Does uremia cause vascular dysfunction? *Kidney Blood Press Res* 2011; **34**: 284-290 [PMID: 21691132 DOI: 10.1159/000327131]

27 **Herbrig K**, Pistrosch F, Oelschlaegel U, Wichmann G, Wagner A, Foerster S, Richter S, Gross P, Passauer J. Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. *Am J Kidney Dis* 2004; **44**: 840-849 [PMID: 15492950 DOI: 10.1053/j.ajkd.2004.08.001]

28 **Jourde-Chiche N**, Dou L, Sabatier F, Calaf R, Cerini C, Robert S, Camoin-Jau L, Charpiot P, Argiles A, Dignat-George F, Brunet P. Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. *J Thromb Haemost* 2009; **7**: 1576-1584 [PMID: 19583820 DOI: 10.1111/j.1538-7836.2009.03540.x]

29 **Neirynck N**, Glorieux G, Boelaert J, Schepers E, Liabeuf S, Dhondt A, Massy Z, Vanholder R. Uremia-related oxidative stress in leukocytes is not triggered by β2-microglobulin. *J Ren Nutr* 2013; **23**: 456-463 [PMID: 24016624 DOI: 10.1053/j.jrn.2013.07.002.]

30 **Zumrutdal A**, Demircan S, Seydaoglu G, Singan M, Sezer S, Ozdemir FN, Haberal M. Atherosclerosis in haemodialysis patients without significant comorbidities: determinants of progression. *Nephrology (Carlton)* 2006; **11**: 489-493 [PMID: 17199784 DOI: 10.1111/j.1440-1797.2006.00694.x]

31 **Kals J**, Zagura M, Serg M, Kampus P, Zilmer K, Unt E, Lieberg J, Eha J, Peetsalu A, Zilmer M. β2-microglobulin, a novel biomarker of peripheral arterial disease, independently predicts aortic stiffness in these patients. *Scand J Clin Lab Invest* 2011; **71**: 257-263 [PMID: 21314441 DOI: 10.3109/00365513.2011.558108]

32 **Real de Asúa D**, Puchades R, García-Polo I, Suárez C. A Study on the Relationship between Serum Beta 2-Microglobulin Levels, Underlying Chronic Kidney Disease, and Peripheral Arterial Disease in High-Vascular-Risk Patients. *Int Cardiovasc Res J* 2012; **6**: 107-112 [PMID: 24757603]

33 **Busti C**, Migliacci R, Falcinelli E, Gresele P. Plasma levels of beta(2)-microglobulin, a biomarker of peripheral arterial disease, are not affected by maximal leg exercise in patients with intermittent claudication. *Atherosclerosis* 2009; **203**: 38-40 [PMID: 18674763 DOI: 10.1016/j.atherosclerosis.2008.06.023]

34 **Jovanović D**, Krstivojević P, Obradović I, Durdević V, Dukanović L. Serum cystatin C and beta2-microglobulin as markers of glomerular filtration rate. *Ren Fail* 2003; **25**: 123-133 [PMID: 12617340 DOI: 10.1081/JDI-120017475]

35 **Zumrutdal A**, Baltali M, Micozkadioglu H, Torun D, Sezer S, Ozdemir FN, Haberal M. Determinants of coronary artery disease in nondiabetic hemodialysis patients: a matched case-control study. *Ren Fail* 2007; **29**: 67-71 [PMID: 17365912 DOI: 10.1080/08860220601039056]

36 **Kiu Weber CI,** Duchateau-Nguyen G, Solier C, Schell-Steven A, Hermosilla R, Nogoceke E, Block G. Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4. *Clin Kidney J* 2014; **7**: 167-173 [PMID: 24683472]

37 **Nead KT**, Zhou MJ, Caceres RD, Sharp SJ, Wehner MR, Olin JW, Cooke JP, Leeper NJ. Usefulness of the addition of beta-2-microglobulin, cystatin C and C-reactive protein to an established risk factors model to improve mortality risk prediction in patients undergoing coronary angiography. *Am J Cardiol* 2013; **111**: 851-856 [PMID: 23290308 DOI: 10.1016/j.amjcard.2012.11.055]

38 **Kawai K**, Kawashima S, Miyazaki T, Tajiri E, Mori M, Kitazaki K, Shirotani T, Inatome T, Yamabe H, Hirata K, Yokoyama M. Serum beta2-microglobulin concentration as a novel marker to distinguish levels of risk in acute heart failure patients. *J Cardiol* 2010; **55**: 99-107 [PMID: 20122555 DOI: 10.1016/j.jjcc.2009.10.003]

39 **Liu YS**, Wang X, Jiang WD, Huang ZW, Wang YM, Hao L, Xing JL, Wang L, Liu XX, Lounsbury P, Zhang M, Lu QH. Circulating levels of β2-microglobulin and cystatin C are associated with left atrial size: additional link between the kidney and the heart. *Clin Nephrol* 2013; **80**: 168-176 [PMID: 23849305 DOI: 10.5414/CN107689]

40 **Saijo Y**, Utsugi M, Yoshioka E, Horikawa N, Sato T, Gong Y, Kishi R. Relationship of beta2-microglobulin to arterial stiffness in Japanese subjects. *Hypertens Res* 2005; **28**: 505-511 [PMID: 16231756]

41 **Raikou VD**, Tentolouris N, Kyriaki D, Evaggelatou A, Tzanatou H. β2-Microglobulin, pulse pressure and metabolic alterations in hemodialysis patients. *Nephron Clin Pract* 2011; **117**: c237-c245 [PMID: 20805697 DOI: 10.1159/000320193]

42 **Cheung AK**, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. *J Am Soc Nephrol* 2006; **17**: 546-555 [PMID: 16382021]

43 **Okuno S**, Ishimura E, Kohno K, Fujino-Katoh Y, Maeno Y, Yamakawa T, Inaba M, Nishizawa Y. Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. *Nephrol Dial Transplant* 2009; **24**: 571-577 [PMID: 18799606 DOI: 10.1093/ndt/gfn521]

44 **Liabeuf S**, Lenglet A, Desjardins L, Neirynck N, Glorieux G, Lemke HD, Vanholder R, Diouf M, Choukroun G, Massy ZA. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. *Kidney Int* 2012; **82**: 1297-1303 [PMID: 22895515 DOI: 10.1038/ki.2012.301]

45 **Amighi J**, Hoke M, Mlekusch W, Schlager O, Exner M, Haumer M, Pernicka E, Koppensteiner R, Minar E, Rumpold H, Schillinger M, Wagner O. Beta 2 microglobulin and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. *Stroke* 2011; **42**: 1826-1833 [PMID: 21546482 DOI: 10.1161/STROKEAHA.110.600312]

46 **Cheung AK**, Greene T, Leypoldt JK, Yan G, Allon M, Delmez J, Levey AS, Levin NW, Rocco MV, Schulman G, Eknoyan G. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. *Clin J Am Soc Nephrol* 2008; **3**: 69-77 [PMID: 18057309]

47 **Astor BC**, Muth B, Kaufman DB, Pirsch JD, Michael Hofmann R, Djamali A. Serum β2-microglobulin at discharge predicts mortality and graft loss following kidney transplantation. *Kidney Int* 2013; **84**: 810-817 [PMID: 23657143 DOI: 10.1038/ki.2013.172]

48 **Yokoyama K**, Yoshida H, Matsuo N, Maruyama Y, Kawamura Y, Yamamoto R, Hanaoka K, Ikeda M, Yamamoto H, Nakayama M, Kawaguchi Y, Hosoya T. Serum beta2 microglobulin (beta2MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients. *Clin Nephrol* 2008; **69**: 121-126 [PMID: 18218305]

49 **Nakamoto H**, Hamada C, Shimaoka T, Sekiguchi Y, Io H, Kaneko K, Horikoshi S, Tomino Y. Accumulation of advanced glycation end products and beta 2-microglobulin in fibrotic thickening of the peritoneum in long-term peritoneal dialysis patients. *J Artif Organs* 2014; **17**: 60-68 [PMID: 24337623 DOI: 10.1007/s10047-013-0741-1]

50 **Foster MC**, Inker LA, Levey AS, Selvin E, Eckfeldt J, Juraschek SP, Coresh J. Novel filtration markers as predictors of all-cause and cardiovascular mortality in US adults. *Am J Kidney Dis* 2013; **62**: 42-51 [PMID: 23518194 DOI: 10.1053/j.ajkd.2013.01.016]

51 **Astor BC**, Shafi T, Hoogeveen RC, Matsushita K, Ballantyne CM, Inker LA, Coresh J. Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. *Am J Kidney Dis* 2012; **59**: 653-662 [PMID: 22305758 DOI: 10.1053/j.ajkd.2011.11.042]

52 **Canaud B**, Morena M, Cristol JP, Krieter D. Beta2-microglobulin, a uremic toxin with a double meaning. *Kidney Int* 2006; **69**: 1297-1299 [PMID: 16612412]

**P-Reviewer:** Eirini G, Hernan T, Sertoglu E, Sun Z **S-Editor:** Tian YL

 **L-Editor: E-Editor:**